CD4 and AIDS: A Cox multivariate analysis indicated that darunavir did not lead to a significantly higher risk of TF (aHR 1.18, 95% CI 0.79–1.77, p = 0.412) when compared to dolutegravir, after adjusting for AIDS-presenting, absolute CD4 count, CD4 percentage and CD4/CD8 ratio at baseline.